Published December 15, 2020
| Version v1
Journal article
Open
Therapeutic genetic variation revealed in diverse Hsp104 homologs
Creators
-
March, Zachary M.1
- Sweeney, Katelyn1
- Kim, Hanna2
- Yan, Xiaohui1
- Castellano, Laura M.1
-
Jackrel, Meredith E.1
- Lin, Jiabei1
- Chuang, Edward1
- Gomes, Edward1
- Willicott, Corey W.1
- Michalska, Karolina3
- Jedrzejczak, Robert P.4
- Joachimiak, Andrzej3
-
Caldwell, Kim A.2
- Caldwell, Guy A.2
- Shalem, Ophir1
-
Shorter, James1
- 1. University of Pennsylvania
- 2. University of Alabama
- 3. University of Chicago
- 4. Argonne National Laboratory
Description
The AAA+ protein disaggregase, Hsp104, increases fitness under stress by reversing stress-induced protein aggregation. Natural Hsp104 variants might exist with enhanced, selective activity against neurodegenerative disease substrates. However, natural Hsp104 variation remains largely unexplored. Here, we screened a cross-kingdom collection of Hsp104 homologs in yeast proteotoxicity models. Prokaryotic ClpG reduced TDP-43, FUS, and a-synuclein toxicity, whereas prokaryotic ClpB and hyperactive variants were ineffective. We uncovered therapeutic genetic variation among eukaryotic Hsp104 homologs that specifically antagonized TDP-43 condensation and toxicity in yeast and TDP-43 aggregation in human cells. We also uncovered distinct eukaryotic Hsp104 homologs that selectively antagonized a-synuclein condensation and toxicity in yeast and dopaminergic neurodegeneration in C. elegans. Surprisingly, this therapeutic variation did not manifest as enhanced disaggregase activity, but rather as increased passive inhibition of aggregation of specific substrates. By exploring natural tuning of this passive Hsp104 activity, we elucidated enhanced, substrate-specific agents that counter proteotoxicity underlying neurodegeneration.
Data availability
All data generated or analysed during this study are included in the manuscript.Files
elife-57457-v2.pdf
Files
(9.1 MB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:a562505787c22aab85fccc8aeadbc7f9 |
8.8 MB | Preview Download |
|
md5:a6c9ca299973f8e2c148c2c2ad5c57cb
|
261.6 kB | Preview Download |
Additional details
Identifiers
- DOI
- 10.7554/eLife.57457
- Other
- oai:uchicago.tind.io:9977
Funding
- National Institutes of Health
- R01GM099836
- Muscular Dystrophy Association
- ALS Association
- Life Extension Foundation
- Linda Montague Pechenik
- Johns Hopkins University
- Target ALS
- National Science Foundation
- DGE-0822
- Alzheimer's Association
- Research Fellowship
- Warren Alpert Foundation
- Distinguished Scholars Fellowship
- Blavatnik Family Foundation
- National Institutes of Health
- T32GM071399
- National Institutes of Health
- F31NS101807
- National Institutes of Health
- T32GM008076